Abstract | BACKGROUND: METHODS: A large, well-characterised series of 1332 primary breast cancer patients with long-term clinical follow-up was assessed for P38 expression by immunohistochemistry. Association of clinicopathological factors and a panel of breast cancer biomarkers was determined by chi-squared test, and multivariate survival analysis was performed using Cox Proportional Hazards regression modelling. RESULTS: This study shows that nuclear P38 is co-expressed with nuclear hormone receptors (p < 0.001) and is an independent prognostic marker of good long-term clinical outcome in primary breast cancer (hazard ratio 0.796, 95% confidence interval 0.662-0.957, p = 0.015). Significant association was found between expression of P38 and markers of DNA repair including nuclear BRCA1 and RAD51, and cleaved PARP1 (all p < 0.001). CONCLUSIONS: The findings support the proposed role for P38 as a tumour suppressor in breast cancer via upregulation of DNA repair proteins and provide novel hypothesis-generating information on the potential role of P38 in adjuvant therapy decision making.
|
Authors | Simon J Johnston, Dena Ahmad, Mohammed A Aleskandarany, Sasagu Kurozumi, Chris C Nolan, Maria Diez-Rodriguez, Andrew R Green, Emad A Rakha |
Journal | BMC cancer
(BMC Cancer)
Vol. 18
Issue 1
Pg. 1027
(Oct 23 2018)
ISSN: 1471-2407 [Electronic] England |
PMID | 30352570
(Publication Type: Journal Article)
|
Chemical References |
- Biomarkers, Tumor
- Receptors, Cytoplasmic and Nuclear
- p38 Mitogen-Activated Protein Kinases
|
Topics |
- Adult
- Aged
- Biomarkers, Tumor
(biosynthesis)
- Breast Neoplasms
(metabolism, pathology, physiopathology)
- DNA Repair
- Female
- Humans
- Middle Aged
- Prognosis
- Receptors, Cytoplasmic and Nuclear
(biosynthesis)
- Retrospective Studies
- p38 Mitogen-Activated Protein Kinases
(biosynthesis, genetics)
|